A phase III study of lenalidomide maintenance after debulking with gemcitabine or liposomal doxorubicin +/radiotherapy in patients with advanced cutaneous Tcell lymphoma not previously treated with intravenous chemotherapy

Trial Profile

A phase III study of lenalidomide maintenance after debulking with gemcitabine or liposomal doxorubicin +/radiotherapy in patients with advanced cutaneous Tcell lymphoma not previously treated with intravenous chemotherapy

Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Doxorubicin liposomal; Gemcitabine
  • Indications Cutaneous T cell lymphoma; Mycosis fungoides; Sezary syndrome
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 01 Dec 2013 Accrual to date is 27% according to United Kingdom Clinical Research Network.
    • 28 Nov 2013 Accrual to date is 13% according to United Kingdom Clinical Research Network.
    • 05 Oct 2013 Status of the trial in Germany is suspended as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top